Pacific Biosciences Of California (PACB) Latest Stock Analysis Report – Oct 15, 2026, 4:00 PM ET
Updated Oct 15, 2026, 4:00 PM ET
- Closed at $1.96, -1.51% vs the prior close of $1.99.
- Volume 12.62M shares, 1.0x its 50-day average.
- No new SEC filings since the prior session.
- No new insider buys or sales reported since the prior session.
PACB dips 1.5% to $1.96, 4 down days in a row. Closed at $1.96, -1.51% vs the prior close of $1.99. Day range $1.86–$2.00, opened at $1.93.
PACB daily analysis — what happened
A plain-English, data-only note written after every US trading day. Newest first; older days stay archived below.
Oct 15, 2026 — PACB dips 1.5% to $1.96, 4 down days in a row
- Closed at $1.96, -1.51% vs the prior close of $1.99. Day range $1.86–$2.00, opened at $1.93.
- Volume was 12.62M shares, 1.0x its 50-day average of 12.05M.
- Price is +23.2% vs its 50-day average ($1.59) and +22.8% vs its 200-day average ($1.60).
- 52-week range $1.07–$3.44; today's close sits at 38% of that range, 43.0% below the 52-week high.
- That makes 4 straight losses.
Oct 14, 2026 — PACB dips 2.9% to $1.99, 3 down days in a row
- Closed at $1.99, -2.93% vs the prior close of $2.05. Day range $1.95–$2.08, opened at $2.00.
- Volume was 9.21M shares, 0.8x its 50-day average of 11.99M.
- Price is +26.1% vs its 50-day average ($1.58) and +24.8% vs its 200-day average ($1.60).
- 52-week range $1.07–$3.44; today's close sits at 39% of that range, 42.2% below the 52-week high.
- That makes 3 straight losses.
Oct 13, 2026 — PACB dips 2.4% to $2.05
- Closed at $2.05, -2.38% vs the prior close of $2.10. Day range $1.99–$2.14, opened at $2.07.
- Volume was 12.28M shares, 1.0x its 50-day average of 11.82M.
- Price is +30.8% vs its 50-day average ($1.57) and +28.6% vs its 200-day average ($1.59).
- 52-week range $1.07–$3.44; today's close sits at 41% of that range, 40.4% below the 52-week high.
Oct 12, 2026 — PACB slides 9.9% to $2.10
- Closed at $2.10, -9.87% vs the prior close of $2.33. Day range $2.01–$2.29, opened at $2.24.
- Volume was 12.08M shares, 1.0x its 50-day average of 11.64M.
- Price is +35.1% vs its 50-day average ($1.55) and +31.8% vs its 200-day average ($1.59).
- 52-week range $1.07–$3.44; today's close sits at 43% of that range, 39.0% below the 52-week high.
Oct 9, 2026 — PACB rises 1.3% to $2.33
- Closed at $2.33, +1.30% vs the prior close of $2.30. Day range $2.21–$2.47, opened at $2.36.
- Volume was 12.82M shares, 1.1x its 50-day average of 11.44M.
- Price is +51.3% vs its 50-day average ($1.54) and +46.4% vs its 200-day average ($1.59).
- 52-week range $1.07–$3.44; today's close sits at 53% of that range, 32.3% below the 52-week high.
Oct 8, 2026 — PACB slides 15.4% to $2.30 on 2.2x normal volume
- Closed at $2.30, -15.44% vs the prior close of $2.72. Day range $2.22–$2.69, opened at $2.63.
- Volume was 24.14M shares, 2.2x its 50-day average of 11.10M — unusually heavy trading.
- Price is +51.0% vs its 50-day average ($1.52) and +44.7% vs its 200-day average ($1.59).
- 52-week range $1.07–$3.44; today's close sits at 52% of that range, 33.1% below the 52-week high.
Oct 7, 2026 — PACB rises 0.7% to $2.72 on 1.9x normal volume
- Closed at $2.72, +0.74% vs the prior close of $2.70. Day range $2.50–$2.74, opened at $2.62.
- Volume was 20.37M shares, 1.9x its 50-day average of 10.85M — unusually heavy trading.
- Price is +80.7% vs its 50-day average ($1.51) and +71.4% vs its 200-day average ($1.59).
- 52-week range $1.07–$3.44; today's close sits at 70% of that range, 20.9% below the 52-week high.
Oct 6, 2026 — PACB slides 5.9% to $2.70 on 4.7x normal volume
- Closed at $2.70, -5.92% vs the prior close of $2.87. Day range $2.43–$3.44, opened at $3.02.
- Volume was 47.11M shares, 4.7x its 50-day average of 10.05M — unusually heavy trading.
- Price is +82.6% vs its 50-day average ($1.48) and +70.6% vs its 200-day average ($1.58).
- 52-week range $1.07–$3.44; today's close sits at 69% of that range, 21.5% below the 52-week high.
Oct 5, 2026 — PACB jumps 13.0% to $2.87, a 52-week high on 2.7x normal volume
- Closed at $2.87, +12.99% vs the prior close of $2.54. Day range $2.51–$2.92, opened at $2.53.
- Volume was 26.25M shares, 2.7x its 50-day average of 9.68M — unusually heavy trading.
- Price is +97.7% vs its 50-day average ($1.45) and +81.8% vs its 200-day average ($1.58).
- 52-week range $1.07–$2.92; today's close sits at 97% of that range, 1.7% below the 52-week high.
- That makes 8 straight gains.
Oct 2, 2026 — PACB rises 1.2% to $2.54, a 6-month high on 2.8x normal volume
- Closed at $2.54, +1.20% vs the prior close of $2.51. Day range $2.44–$2.65, opened at $2.50.
- Volume was 26.01M shares, 2.8x its 50-day average of 9.30M — unusually heavy trading.
- Price is +78.6% vs its 50-day average ($1.42) and +61.3% vs its 200-day average ($1.57).
- 52-week range $1.07–$2.73; today's close sits at 89% of that range, 7.0% below the 52-week high.
- That makes 7 straight gains.
PACB latest news & SEC filings
Every SEC filing by or about PACB in the last 120 days, explained in plain English. Updated daily, with a same-day refresh for new filings.
Oct 8, 2026 · 4 — Insider trade report (Form 4)
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
- Gibson James R Ii converted options/RSUs into 500,000 shares at $1.18 (≈$590.00K) on Oct 6, 2026; now holds 1,745,663
- Gibson James R Ii sold 661,815 shares at $3.11 (≈$2.06M) on Oct 6, 2026; now holds 1,083,848
Open-market purchases (P) and sales (S) are shown in colour; awards, exercises and tax withholding are routine pay-related moves. Many sales are pre-planned under 10b5-1 plans.
Oct 6, 2026 · 144 — Notice of proposed sale (Form 144)
Notice of proposed sale (Form 144) — an insider or affiliate plans to sell restricted or control shares
A notice of intent, not a completed sale. Any actual sale by a director or officer shows up later on Form 4.
Aug 18, 2026 · 4 — Insider trade report (Form 4)
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
- Van Oene Mark sold 26,911 shares at $1.13 (≈$30.41K) on Aug 17, 2026
Open-market purchases (P) and sales (S) are shown in colour; awards, exercises and tax withholding are routine pay-related moves. Many sales are pre-planned under 10b5-1 plans.
Aug 17, 2026 · 144 — Notice of proposed sale (Form 144)
Notice of proposed sale (Form 144) — an insider or affiliate plans to sell restricted or control shares
A notice of intent, not a completed sale. Any actual sale by a director or officer shows up later on Form 4.
Aug 14, 2026 · SCHEDULE 13G/A — Update to a passive 5%+ stake (13G)
Update to a passive 5%+ stake (13G)
Filed by an outside investor (not the company). It reports a holding of more than 5% of a share class; percentage and holder name are in the filing.
Aug 11, 2026 · 4 — Insider trade report (Form 4)
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
Insider holdings update with no common-stock transactions in the table (often options or derivative awards only).
Aug 7, 2026 · S-8 — Registration of shares for employee stock plans (S-8)
Registration of shares for employee stock plans (S-8)
Aug 6, 2026 · 10-Q — Quarterly report (unaudited financial statements for the quarter)
Quarterly report (unaudited financial statements for the quarter)
Quarter ended Jun 30, 2026:
- Revenue: $39.01M (prior year $39.77M) (-1.9% vs Jun 30, 2025)
- Net income: -$44.74M (prior year -$41.93M) (loss widened vs Jun 30, 2025)
- Diluted EPS: -$0.14 (prior year -$0.14) ( vs Jun 30, 2025)
Aug 5, 2026 · 8-K — Current report
Current report — a filing companies must make within 4 business days of a major event
- Item 2.02 — Reported results of operations (earnings release).
- Item 2.05 — Costs tied to exiting activities / restructuring.
- Item 5.02 — Change in directors or officers (appointment, departure or pay).
- Item 7.01 — Released information under Regulation FD (e.g. a presentation or press release).
This is a results-day filing: the earnings press release is attached as an exhibit.
Jul 9, 2026 · 8-K — Current report
Current report — a filing companies must make within 4 business days of a major event
- Item 5.02 — Change in directors or officers (appointment, departure or pay).
Things to know before you trade PACB
- Last results release: Aug 5, 2026 (8-K Item 2.02). Previous ones: May 7, 2026, Feb 12, 2026, Jan 12, 2026. Based on that rhythm, the next report is likely around Nov 4, 2026 — an estimate, not a confirmed date.
- How much it moves: over the last 20 sessions the average daily move was 6.52% (largest 29.5%). That is a volatile stock.
- Liquidity: about 20.22M shares (≈$39.64M) trade per day on average.
- 52-week position: $1.96 vs a range of $1.07–$3.44 (38% of the range).
- Dividends: no cash dividends in the last 2 years.
- Splits: none in the last 2 years.
- Insider trades (Form 4, last 12 months, recent 25 shown): 0 open-market buys, 11 sales; latest: Oene Mark Van sold 26,911 shares on Aug 17, 2026.
- Latest filings: 10-Q Aug 6, 2026; 8-K Aug 5, 2026; 8-K Jul 9, 2026.
- Share count: 310.83M shares outstanding (Jul 31, 2026), +3.5% vs a year earlier.
- Listing: Nasdaq · industry: Laboratory Analytical Instruments.
PACB market data (last 20 sessions)
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 15, 2026 | 1.93 | 2.00 | 1.86 | 1.96 | 12.62M |
| Oct 14, 2026 | 2.00 | 2.08 | 1.95 | 1.99 | 9.21M |
| Oct 13, 2026 | 2.07 | 2.14 | 1.99 | 2.05 | 12.28M |
| Oct 12, 2026 | 2.24 | 2.29 | 2.01 | 2.10 | 12.08M |
| Oct 9, 2026 | 2.36 | 2.47 | 2.21 | 2.33 | 12.82M |
| Oct 8, 2026 | 2.63 | 2.69 | 2.22 | 2.30 | 24.14M |
| Oct 7, 2026 | 2.62 | 2.74 | 2.50 | 2.72 | 20.37M |
| Oct 6, 2026 | 3.02 | 3.44 | 2.43 | 2.70 | 47.11M |
| Oct 5, 2026 | 2.53 | 2.92 | 2.51 | 2.87 | 26.25M |
| Oct 2, 2026 | 2.50 | 2.65 | 2.44 | 2.54 | 26.01M |
| Oct 1, 2026 | 2.34 | 2.56 | 2.32 | 2.51 | 35.87M |
| Sep 30, 2026 | 1.84 | 2.46 | 1.84 | 2.37 | 80.39M |
| Sep 29, 2026 | 1.68 | 1.85 | 1.63 | 1.83 | 17.42M |
| Sep 28, 2026 | 1.60 | 1.80 | 1.59 | 1.71 | 21.28M |
| Sep 25, 2026 | 1.57 | 1.63 | 1.52 | 1.62 | 11.36M |
| Sep 24, 2026 | 1.40 | 1.59 | 1.38 | 1.58 | 11.10M |
| Sep 23, 2026 | 1.45 | 1.47 | 1.39 | 1.41 | 5.26M |
| Sep 22, 2026 | 1.38 | 1.48 | 1.36 | 1.47 | 7.85M |
| Sep 21, 2026 | 1.37 | 1.40 | 1.34 | 1.36 | 6.13M |
| Sep 18, 2026 | 1.38 | 1.40 | 1.34 | 1.37 | 4.96M |
About Pacific Biosciences Of California
Pacific Biosciences Of California (PACB) is listed on the Nasdaq and classified by the SEC under “Laboratory Analytical Instruments”. Its business address is in MENLO PARK, CA. State of incorporation: DE. Fiscal year ends December 31. SEC CIK 1299130.
PACB board of directors & executives
From SEC Form 3/4/5 insider filings made in the last 12 months (date = latest filing).
Directors
| Name | Role | Latest filing |
|---|---|---|
| William W. Ericson | Director | Jun 4, 2026 |
| Christopher Gibson | Director | Jun 4, 2026 |
| Randall S Livingston | Director | Jun 4, 2026 |
| John F Milligan | Director | Jun 4, 2026 |
| Marshall Mohr | Director | Jun 4, 2026 |
| Kathy Ordonez | Director | Jun 4, 2026 |
| Christopher M Smith | Director | Jun 4, 2026 |
| Hannah Valantine | Director | Jun 4, 2026 |
Executive officers
| Name | Title | Latest filing |
|---|---|---|
| Michele Farmer | See Remarks | Mar 4, 2026 |
| James R Ii Gibson | See Remarks | Apr 3, 2026 |
| Christian O Henry | See Remarks | Mar 4, 2026 |
| Oene Mark Van | See Remarks | Aug 18, 2026 |
Recent insider buys & sales
| Date | Insider | Type | Shares | Price |
|---|---|---|---|---|
| Aug 17, 2026 | Oene Mark Van | Sale | 26,911 | $1.13 |
| Apr 1, 2026 | James R Ii Gibson | Sale | 88,185 | $1.37 |
| Mar 3, 2026 | Michele Farmer | Sale | 2,979 | $1.51 |
| Mar 3, 2026 | Christian O Henry | Sale | 12,497 | $1.51 |
| Mar 3, 2026 | Oene Mark Van | Sale | 6,504 | $1.51 |
| Feb 18, 2026 | Christian O Henry | Sale | 140,874 | $1.63 |
| Feb 18, 2026 | Michele Farmer | Sale | 14,952 | $1.63 |
| Feb 18, 2026 | Oene Mark Van | Sale | 55,107 | $1.63 |
| Feb 17, 2026 | Christian O Henry | Sale | 331,793 | $1.58 |
| Feb 17, 2026 | Michele Farmer | Sale | 35,215 | $1.58 |
| Feb 17, 2026 | Oene Mark Van | Sale | 129,790 | $1.58 |
PACB financials (annual, from XBRL filings)
| Fiscal year end | Revenue | Net income | Diluted EPS | Operating cash flow |
|---|---|---|---|---|
| Dec 31, 2025 | — | $-546.38M | -1.82 | $-111.21M |
| Dec 31, 2024 | — | $-309.85M | -1.59 | $-206.06M |
| Dec 31, 2023 | — | $-306.74M | -1.21 | $-259.17M |
| Dec 31, 2022 | — | $-314.25M | -1.40 | $-263.21M |
| Dec 31, 2021 | — | $-181.22M | -0.89 | $-111.18M |
Latest balance sheet: total assets $751.85M, total liabilities $785.06M, cash $61.00M (as of Jun 30, 2026).
PACB earnings / results-day log
| Date | Filing | Close that day |
|---|---|---|
| Aug 5, 2026 | 8-K Item 2.02 (results) | $1.30 |
| May 7, 2026 | 8-K Item 2.02 (results) | $1.65 |
| Feb 12, 2026 | 8-K Item 2.02 (results) | $1.84 |
| Jan 12, 2026 | 8-K Item 2.02 (results) | $2.01 |
| Nov 5, 2025 | 8-K Item 2.02 (results) | $1.92 |
| Aug 7, 2025 | 8-K Item 2.02 (results) | $1.26 |
| May 8, 2025 | 8-K Item 2.02 (results) | $1.20 |
| Apr 9, 2025 | 8-K Item 2.02 (results) | $1.45 |
| Feb 13, 2025 | 8-K Item 2.02 (results) | $1.48 |
| Jan 14, 2025 | 8-K Item 2.02 (results) | $1.85 |
| Nov 7, 2024 | 8-K Item 2.02 (results) | $2.45 |
| Aug 7, 2024 | 8-K Item 2.02 (results) | — |
Related stocks · Laboratory Analytical Instruments
Illumina (ILMN)Waters (WAT)Mettler Toledo International Inc/ (MTD)Revvity (RVTY)Agilent Technologies (A)10x Genomics (TXG)Bruker (BRKR)Avantor (AVTR)Bio-Rad Laboratories (BIO)Alamar Biosciences (ALMR)
Popular today
Micron Technology (MU)Spdr S&P 500 Etf (SPY)Nvidia (NVDA)Sandisk (SNDK)AMD (AMD)Space Exploration Technologies (SPCX)Intel (INTC)Apple (AAPL)Microsoft (MSFT)Meta Platforms (META)Broadcom (AVGO)Tesla (TSLA)
More on PACB
Information only, not investment advice. BuyMeWhiskey is not a registered investment adviser or broker-dealer; nothing here is a recommendation to buy, sell or hold any security, and there are no price targets. Data comes from SEC EDGAR filings and public end-of-day market data and may be delayed or contain errors. Verify with the company's filings before making decisions. Prices: end-of-day data as of Oct 15, 2026, 4:00 PM ET. Filings: SEC EDGAR. Updated after every US trading day.